esrd
condit
kidney
function
sever
compromis
patient
esrd
requir
kidney
transplant
frequent
hemodialysi
prevent
clinic
complic
death
due
buildup
wast
product
blood
critic
monitor
kidney
function
patient
diagnos
convers
acut
diseas
state
examin
numer
potenti
renal
function
biomark
saliva
esrd
patient
patient
ideal
studi
cohort
concentr
blood
analyt
decreas
dramat
dialysi
noninvas
rapid
method
monitor
kidney
function
could
reduc
need
period
hospit
visit
blood
test
patient
could
potenti
use
evalu
dialysi
efficaci
esrd
patient
esrd
patient
variou
state
diseas
progress
enrol
dialysi
clinic
boston
univers
medic
center
bumc
ask
donat
saliva
undergo
dialysi
weekli
basi
period
panel
candid
analyt
screen
consist
trend
saliva
sampl
preliminari
test
perform
sodium
na
potassium
k
magnesium
calcium
chlorid
phosphat
nitrit
ion
ph
thiol
uric
acid
ua
amylas
lactoferrin
esteras
total
protein
nucleic
acid
glucos
level
tabl
analyt
shown
ital
exhibit
differ
saliva
composit
initi
screen
analyt
list
bold
type
na
ua
show
best
correl
monitor
extens
studi
collect
saliva
sampl
regular
time
interv
throughout
dialysi
determin
whether
analyt
good
indic
monitor
efficaci
dialysi
studi
conduct
saliva
sampl
collect
esrd
patient
immedi
dialysi
well
hourli
interv
throughout
treatment
saliva
level
ua
consist
track
dialysi
exhibit
decreas
concentr
throughout
process
rate
decreas
howev
vari
individu
two
analyt
select
evalu
simpl
colorimetr
test
strip
develop
semiquantit
determin
concentr
ua
saliva
approach
offer
potenti
method
monitor
renal
statu
chromatographi
paper
impregn
ua
detect
chemistri
follow
adhes
test
paper
onto
vinyl
support
materi
colorimetr
test
paper
salivari
base
griess
reaction
common
method
nitrit
quantif
colorimetr
test
paper
ua
use
sodium
bicinchonin
chelat
method
brief
immers
solut
produc
test
pad
color
intens
proport
concentr
ua
sampl
develop
calibr
color
chart
visual
determin
concentr
analyt
fig
figur
demonstr
color
chang
test
strip
immers
archiv
saliva
supernat
sampl
collect
esrd
patient
follow
studi
test
strip
employ
bumc
dialysi
clinic
salivari
ua
determin
stimul
whole
saliva
collect
esrd
patient
dialysi
test
immedi
use
strip
similarli
sampl
donat
healthi
control
similarli
analyz
use
test
strip
outcom
confirm
earlier
result
test
strip
could
use
follow
ua
concentr
dialysi
fig
pulmonari
inflammatori
diseas
asthma
chronic
obstruct
pulmonari
diseas
copd
becom
increasingli
preval
asthma
affect
nearli
million
american
cost
billion
direct
expenditur
copd
affect
nearli
million
american
anoth
million
estim
live
undiagnos
diseas
goal
develop
portabl
devic
rapidli
monitor
multipl
biomark
saliva
patient
suffer
obstruct
pulmonari
inflammatori
diseas
pathogenesi
pulmonari
inflamm
obstruct
diseas
result
complex
network
special
immun
cell
protein
product
caus
exacerb
includ
allergen
irrit
heatcoldhumid
bacteri
viral
infect
platform
capabl
simultan
monitor
caus
exacerb
well
level
numer
biomark
result
pathogen
respons
would
power
tool
elucid
differ
associ
differ
caus
exacerb
extrins
vs
intrins
monitor
mani
analyt
simultan
salivari
protein
pathogen
fingerprint
could
creat
individu
profil
could
regularli
monitor
elucid
caus
exacerb
evalu
effect
treatment
determin
endogen
cytokin
chemokin
present
detect
concentr
saliva
initi
screen
small
number
archiv
saliva
supernat
sampl
asthmat
healthi
control
use
human
cytokin
array
v
kit
raybiotech
norcross
ga
usa
commerci
avail
test
base
multiplex
immunosorb
assay
elisa
chemiluminesc
detect
provid
qualit
result
identifi
rel
level
cytokin
chemokin
fig
use
method
abl
identifi
number
salivari
cytokin
chemokin
examin
greater
detail
use
secondari
quantit
assay
number
cytokin
chemokin
show
elev
level
pulmonari
inflamm
raybio
cytokin
array
v
examin
quantit
elisa
screen
studi
repres
preliminari
quantit
salivari
screen
result
asthmat
patient
healthi
control
shown
figur
examin
close
singl
analyt
correl
pulmonari
inflammatori
state
elev
level
multipl
analyt
present
patient
cytokin
chemokin
show
potenti
correl
pulmonari
inflamm
investig
confirm
util
asthma
biomark
final
examin
numer
inflammatori
protein
simultan
use
multiplex
assay
hope
develop
better
understand
differ
way
asthma
manifest
differ
patient
assay
cytokin
chemokin
shown
potenti
correl
pulmonari
inflammatori
diseas
exacerb
could
convert
probe
pool
multiplex
screen
studi
perform
multiplex
fiber
optic
measur
diamet
polym
microspher
first
encod
distinct
concentr
fluoresc
europium
dye
microspher
convert
probe
coval
attach
monoclon
antibodi
via
glutaraldehyd
chemistri
probe
recogn
differ
analyt
pool
deposit
well
fiber
optic
array
produc
multiplex
immunoassay
addit
cytokin
chemokin
probe
includ
multiplex
array
modifi
composit
microspher
bead
pool
current
iter
multiplex
cytokin
array
includ
probe
specif
rant
vegf
hypothes
natur
exchang
bacteria
virus
associ
pulmonari
exacerb
upper
respiratori
tract
fluid
saliva
identifi
varieti
organ
develop
multiplex
fiber
optic
sensor
array
screen
saliva
sampl
pathogen
probe
sequenc
specif
polymeras
chain
reaction
pcr
amplicon
pathogen
list
tabl
incorpor
sentrix
beadchip
array
illumina
inc
san
diego
ca
usa
contain
bundl
bead
sensor
respect
oral
control
microorgan
also
includ
verifi
valid
detect
strategi
present
nucleic
acid
detect
approach
involv
pcr
amplif
pathogen
sequenc
follow
direct
hybrid
oligonucleotid
microarray
primer
test
use
cultur
sampl
commerci
avail
extract
bacteri
dna
whole
saliva
sampl
first
centrifug
separ
cell
particul
matter
nucleic
acid
isol
purifi
result
pellet
use
commerci
kit
qiamp
dna
mini
kit
qiagen
inc
amplifi
use
asymmetr
pcr
hybrid
pcr
amplicon
oligonucleotid
array
detect
stain
biotinyl
primer
fluoresc
intens
pcr
product
asthmat
patient
versu
healthi
control
sampl
actinomyc
naeslundii
present
figur
threshold
set
mean
control
plu
one
standard
deviat
interestingli
higher
intens
observ
oral
control
organ
asthmat
saliva
sampl
control
patient
sampl
oligonucleotid
probe
complementari
h
influenza
amplicon
tend
show
higher
fluoresc
intens
asthmat
sampl
threshold
control
seen
figur
patient
popul
limit
asthmat
copd
result
similar
data
shown
oligonucleotid
microarray
approach
detect
respiratori
pathogen
sever
advantag
current
taqman
method
hybrid
pcr
amplif
product
array
incorpor
ad
level
specif
redund
bead
per
fiber
bundl
ensur
hybrid
event
statist
signific
convent
method
typic
slow
unabl
differenti
strain
serotyp
direct
detect
nucleic
acid
pulmonari
pathogen
provid
accur
profil
current
infect
clinic
diagnost
kit
detect
antibodi
respiratori
pathogen
inher
delay
immun
system
respons
continu
antibodi
product
follow
infect
clearanc
sampl
collect
handl
pretreat
encompass
wide
rang
challeng
devic
especi
saliva
diagnost
interfac
devic
saliva
sampl
must
clean
sampl
event
elimin
possibl
interpati
sampl
contamin
develop
dispos
microfluid
cassett
incorpor
necessari
extract
concentr
amplif
detect
chemistri
embed
array
includ
cassett
contain
sensor
analog
beadchip
design
use
analyt
screen
basi
experi
hybrid
kinet
limit
detect
improv
agit
sampl
across
sensor
microfluid
platform
also
employ
thermopneumat
flow
oscil
detect
chamber
studi
report
analyz
saliva
esrd
patient
asthmat
determin
whether
sampl
matrix
could
use
system
diseas
diagnosi
monitor
esrd
abl
identifi
two
salivari
analyt
ua
elev
predialysi
patient
shown
reduc
follow
dialysi
detect
chemistri
two
analyt
convert
colorimetr
test
strip
format
rapid
facil
semiquantit
determin
ua
saliva
test
strip
notabl
advantag
screen
method
name
abil
provid
instantan
measur
two
analyt
simultan
undilut
saliva
without
expens
instrument
forese
test
strip
potenti
improv
qualiti
life
esrd
especi
patient
individu
could
monitor
salivari
analyt
level
home
therebi
elimin
period
visit
clinic
andor
invas
blood
test
asthma
goal
elucid
complex
network
protein
pathogen
implic
pulmonari
exacerb
use
whole
saliva
diagnost
fluid
incorpor
assay
promis
pulmonari
inflamm
biomark
multiplex
platform
saliva
physician
would
abl
make
decis
caus
exacerb
appropri
treatment
option
